Fytexia introduces clinically proven satiety peptides for weight management at SupplySide West

Fytexia extends its weight management range with DNF-10, a selection of peptides from Saccharomyces cerevisiae, proven to enhance the feeling of satiety and reduce food intake

New clinical data on weight management will be revealed at SupplySide West 2018 after Fytexia extended its range of clinically proven weight management solutions with DNF-10.

Obtained from a screening of small molecular weight peptides after proteolysis of Saccharomyces cerevisiae, DNF-10 addresses weight management through a regulation of the mediators of satiety. The low molecular weight peptides (<10kDa) from DNF-10 lower the hypothalamic expression of neuropeptide Y and downregulate ghrelin, our inner hunger-promoter. Over the long term, DNF-10 is proven to also modulate the secretion of leptin, a satiety hormone secreted by our fat cells.

Clinical studies show that a daily intake of 500 mg of DNF-10 significantly decreases the caloric intake of supplemented subjects by 200kcal/day after the first week to reach a total reduction in caloric intake of 600 kcal/day after 2 months. This lower intake of food results in significant body weight loss after four weeks. Measured with computed tomography, the weight loss is from a reduction in fat mass.

Four published clinical studies on a total 135 subjects are available to support these results.

Water-soluble and heat-resistant, DNF-10 is recommended at a dosage of 500 mg/day for the formulation of dietary supplements and functional foods.

solutions, led by the flagship ingredient Sinetrol, a natural fat-burner supported with three clinical studies.

Fytexia will be exhibiting at SupplySide West 8-9 November at booth #4251.

For more details contact Fytexia at lnogier@fytexia.com

Companies